August 25, 2017
Prommune’s HeptaVac reduces lung lesions in H1n1 infected pigs
Prommune has completed completion of its third proof of concept study in pigs for its lead products HeptaVac, a self-adjuvating peptide vaccine cocktail and HISP-P, an immunoactivator and molecular adjuvant both for use in pigs with Swine Influenza A Virus infections.